AKT1 and colorectal cancer: Notably, we found that AKT/mTOR activity was significantly reduced in DDX5 knockdown colorectal cancer cell lines, but the addition of mTOR agonist (MHY1485) significantly reversed the activation of AKT/mTOR signalling pathway.